[go: up one dir, main page]

HK1210706A1 - Inhalable pharmaceutical compositions - Google Patents

Inhalable pharmaceutical compositions

Info

Publication number
HK1210706A1
HK1210706A1 HK15111545.0A HK15111545A HK1210706A1 HK 1210706 A1 HK1210706 A1 HK 1210706A1 HK 15111545 A HK15111545 A HK 15111545A HK 1210706 A1 HK1210706 A1 HK 1210706A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical compositions
inhalable pharmaceutical
inhalable
compositions
pharmaceutical
Prior art date
Application number
HK15111545.0A
Other languages
English (en)
Chinese (zh)
Inventor
．威廉．博施
馬修．卡拉漢
菲利克斯．梅斯特
馬克．諾雷特
艾德裡安．拉塞爾
Original Assignee
Iceutica Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica Holdings Inc filed Critical Iceutica Holdings Inc
Publication of HK1210706A1 publication Critical patent/HK1210706A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15111545.0A 2012-02-28 2015-11-23 Inhalable pharmaceutical compositions HK1210706A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261604435P 2012-02-28 2012-02-28
PCT/IB2013/000708 WO2013128283A2 (en) 2012-02-28 2013-02-28 Inhalable pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1210706A1 true HK1210706A1 (en) 2016-05-06

Family

ID=48628732

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15111545.0A HK1210706A1 (en) 2012-02-28 2015-11-23 Inhalable pharmaceutical compositions
HK18112279.7A HK1252926A1 (zh) 2012-02-28 2015-11-23 可吸入藥物組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18112279.7A HK1252926A1 (zh) 2012-02-28 2015-11-23 可吸入藥物組合物

Country Status (14)

Country Link
US (2) US10022303B2 (ru)
EP (1) EP2819645A2 (ru)
JP (1) JP6231022B2 (ru)
KR (2) KR20150041608A (ru)
CN (2) CN107875127A (ru)
AU (3) AU2013227351B2 (ru)
CA (1) CA2865702C (ru)
HK (2) HK1210706A1 (ru)
IL (1) IL234365B (ru)
NZ (2) NZ629438A (ru)
RU (2) RU2697862C2 (ru)
SG (2) SG11201405243TA (ru)
WO (1) WO2013128283A2 (ru)
ZA (1) ZA201703992B (ru)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014004437A1 (en) 2012-06-25 2014-01-03 Gecko Health Innovations, Inc. Devices, systems, and methods for adherence monitoring and patient interaction
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
JP2016518388A (ja) 2013-04-30 2016-06-23 オティトピック インク． 乾燥粉末配合および使用方法
KR102402909B1 (ko) 2013-08-28 2022-05-27 게코 헬스 이노베이션즈, 인크. 처방 준수 모니터링을 위한 디바이스, 시스템, 및 방법과 소모품 디스펜서의 사용을 모니터링하기 위한 디바이스, 시스템, 및 방법
PL3104854T3 (pl) 2014-02-10 2020-11-30 Respivant Sciences Gmbh Stabilizatory komórek tucznych do leczenia choroby płuc
HUE047319T2 (hu) 2014-02-10 2020-04-28 Respivant Sciences Gmbh Hízósejt-stabilizátorral történõ kezelés szisztémás rendellenességekhez
EP4119131A1 (en) 2014-02-20 2023-01-18 Otitopic Inc. Dry powder formulations for inhalation
US20150283070A1 (en) * 2014-04-08 2015-10-08 Sansa Corporation (Barbados) Inc. Nicotine Formulations and Methods of Making the Same
US10369217B2 (en) * 2014-06-06 2019-08-06 Merck Patent Gmbh Antigen-loaded chitosan nanoparticles for immunotherapy
CA2951690A1 (en) 2014-06-09 2015-12-17 Biometry Inc. Low cost test strip and method to measure analyte
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
KR102666667B1 (ko) * 2014-07-31 2024-05-17 벡추라 인코포레이티드 흡입용 건조 분말 제형
MX392636B (es) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
WO2016176552A1 (en) * 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
US11723864B2 (en) 2015-05-29 2023-08-15 The Texas A&M University System Antimicrobial and anti-inflammatory compositions
AU2016287453A1 (en) * 2015-06-30 2017-09-28 Société des Produits Nestlé S.A. Composition suitable for protecting microorganisms
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
KR101880295B1 (ko) * 2016-01-12 2018-08-02 주식회사 시너지이노베이션 디히드로에르고타민 타트레이트를 포함하는 폐암의 예방 또는 치료용 조성물
JP6323846B2 (ja) * 2016-04-07 2018-05-16 塩野義製薬株式会社 オピオイドを含有する乱用防止製剤
WO2017192993A1 (en) * 2016-05-05 2017-11-09 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
CA3031247A1 (en) 2016-07-19 2018-01-25 Biometry Inc. Methods of and systems for measuring analytes using batch calibratable test strips
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018047002A1 (en) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same
WO2018047013A1 (en) 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
JP2019531308A (ja) 2016-10-07 2019-10-31 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 肺線維症の治療のためのクロモリン組成物
AU2017432640B2 (en) * 2017-09-22 2023-11-30 Vectura Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) * 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR20200117998A (ko) 2018-02-01 2020-10-14 코버스 파마슈티칼스, 인크. 약학적 조성물
EP3749298B1 (en) 2018-02-07 2023-04-05 Lovelace Biomedical Research Institute Inhalable dry powder cytidine analogue composition and method of use as a treatment for cancer
EP3762104A2 (en) 2018-03-07 2021-01-13 ST IP Holding AG Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
IT201800006909A1 (it) * 2018-07-04 2020-01-04 Polvere secca di ambroxolo per uso inalatorio con target bronchiale
US11774363B2 (en) * 2018-08-07 2023-10-03 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
SG11202102653WA (en) 2018-09-18 2021-04-29 St Ip Holding Ag Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones
GB2578093B (en) * 2018-10-09 2020-11-18 Verona Pharma Plc Liquid pharmaceutical composition comprising RPL554 and HFA-134A
EP3673895A1 (en) * 2018-12-28 2020-07-01 Université Libre de Bruxelles Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
US11499904B2 (en) * 2020-02-12 2022-11-15 National Guard Health Affairs In vitro dissolution test method for fluticasone propionate and other inhaled drugs
WO2021186244A1 (en) 2020-03-16 2021-09-23 St Ip Holding Ag Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2-dithiole-3-thiones
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
US20240033222A1 (en) 2020-08-14 2024-02-01 Norton (Waterford) Limited An inhalable formulation of fluticasone propionate and albuterol sulfate
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
KR102488719B1 (ko) * 2020-12-03 2023-01-13 충북대학교 산학협력단 셀레시파그를 함유하는 건조 분말 흡입 제제 및 그 제조방법
KR20230039894A (ko) * 2021-09-14 2023-03-22 한국유나이티드제약 주식회사 코로나 19 바이러스 감염 질환의 예방 또는 치료를 위한 흡입형 약학조성물
WO2023105086A1 (en) * 2021-12-10 2023-06-15 Gudiminchi Rama Krishna Use of glycosylated sugar alcohols
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
WO2023247952A1 (en) * 2022-06-21 2023-12-28 Hovione Scientia Limited Crystalline pharmaceutical composition for inhalation comprising sugar and lipid composite particles and process for manufacture
WO2024009079A1 (en) 2022-07-04 2024-01-11 Hovione Scientia Limited Dry powder inhaler pharmaceutical composition of coated crystalline dry powder for inhalation
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1084994B (it) * 1976-06-09 1985-05-28 Funk Heporaut Kirsti Guarnizione per alberi,in particolare in mulini con agiotatore oppure in mulini colloidali
US5500331A (en) 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5478705A (en) 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9603669D0 (sv) * 1996-10-08 1996-10-08 Astra Ab New combination
CA2328882A1 (en) * 1998-04-18 1999-10-28 Glaxo Group Limited Pharmaceutical aerosol formulation
GB0012261D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
CN100457090C (zh) * 2000-08-31 2009-02-04 斯凯伊药品加拿大公司 磨制颗粒
EP2298279B1 (en) * 2000-11-30 2018-11-14 Vectura Limited Pharmaceutical compositions for inhalation
US20050191357A1 (en) * 2002-03-20 2005-09-01 Yoshiaki Kawashima Method of manufacturing chemical-containing composite particles
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB0321607D0 (en) * 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
WO2005072702A2 (en) * 2004-01-20 2005-08-11 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
US8900555B2 (en) 2006-07-27 2014-12-02 Nektar Therapeutics Insulin derivative formulations for pulmonary delivery
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
MX354829B (es) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
WO2010121323A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd Method for the production of commercial nanoparticle and microparticle powders
AU2009100698B4 (en) * 2009-07-17 2010-04-15 Astrazeneca Ab Combination
RU2555772C2 (ru) * 2009-12-14 2015-07-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Микрочастицы с антибиотиком для ингаляции

Also Published As

Publication number Publication date
CN107875127A (zh) 2018-04-06
JP6231022B2 (ja) 2017-11-15
JP2015508808A (ja) 2015-03-23
US20140065219A1 (en) 2014-03-06
IL234365B (en) 2019-09-26
CN104703584B (zh) 2019-05-31
US20180318170A1 (en) 2018-11-08
CA2865702C (en) 2020-04-28
CA2865702A1 (en) 2013-09-06
US10022303B2 (en) 2018-07-17
CN104703584A (zh) 2015-06-10
WO2013128283A2 (en) 2013-09-06
KR20150041608A (ko) 2015-04-16
NZ722952A (en) 2018-12-21
AU2017213466A1 (en) 2017-08-31
NZ629438A (en) 2016-10-28
RU2019110128A3 (ru) 2020-06-04
RU2697862C2 (ru) 2019-08-21
HK1252926A1 (zh) 2019-06-06
RU2019110128A (ru) 2019-05-08
AU2013227351B2 (en) 2016-06-16
AU2013227351A1 (en) 2014-09-18
WO2013128283A3 (en) 2013-10-31
RU2014139046A (ru) 2016-04-20
KR20200015828A (ko) 2020-02-12
ZA201703992B (en) 2019-12-18
AU2016202881A1 (en) 2016-05-26
SG11201405243TA (en) 2014-09-26
AU2017213466B2 (en) 2019-03-14
SG10201703243QA (en) 2017-06-29
EP2819645A2 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
ZA201703992B (en) Inhalable pharmaceutical compositions
IL230010B (en) Inhalable pharmaceutical ingredients
HK1209638A1 (en) Pharmaceutical compositions
GB201113662D0 (en) Pharmaceutical compositions
AP3656A (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
HK1199821A1 (en) Oral pharmaceutical composition
HK1199822A1 (zh) 口服給藥用醫藥組合物
HK1210710A1 (en) Pharmaceutical composition comprising rebamipide
GB201118181D0 (en) Pharmaceutical compositions
ZA201502987B (en) Pharmaceutical composition
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
EP2714715A4 (en) PHARMACEUTICAL COMPOSITIONS
IL238075A0 (en) pharmaceutical preparations
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions
GB201204810D0 (en) Pharmaceutical compositions
ZA201400751B (en) Pharmaceutical composition
GB201221130D0 (en) New pharmaceutical composition
GB201207701D0 (en) New pharmaceutical composition
GB201207628D0 (en) New pharmaceutical composition